Conscious of difficulties in the translation of in vitro and in vivo results of immune therapy effectiveness to the clinical application, we utilized the RCAS/tv-a system to generate PDGFB-induced gliomas with or without p53 knockdown. This evidence concerns the gene PDGFB and central nervous system cancer.